AI Engines For more Details: Perplexity Kagi Labs You
Antidepressant Effect: Isocarboxazid is used to alleviate symptoms of depression, including persistent sadness, loss of interest or pleasure in activities, changes in appetite or weight, sleep disturbances, fatigue, feelings of worthlessness or guilt, difficulty concentrating, and thoughts of death or suicide. By inhibiting the enzyme monoamine oxidase, isocarboxazid increases the levels of neurotransmitters such as serotonin, dopamine, and norepinephrine in the brain, which are believed to play a role in regulating mood.
Treatment-Resistant Depression: Isocarboxazid is particularly useful in cases of treatment-resistant depression, where other antidepressant medications have not been effective. It may be prescribed when other classes of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs), have failed to produce satisfactory results.
Symptom Improvement: Patients typically experience a gradual improvement in depressive symptoms with isocarboxazid treatment. It may take several weeks for the full therapeutic effect to be realized. It is important for patients to continue taking the medication as prescribed, even if they start to feel better, to prevent a relapse of depression.
Side Effects: Isocarboxazid can cause various side effects, including dizziness, drowsiness, blurred vision, dry mouth, constipation, urinary retention, orthostatic hypotension (a sudden drop in blood pressure upon standing), weight gain, sexual dysfunction, and insomnia. Some individuals may also experience hypertensive crisis, a potentially life-threatening condition characterized by severe headache, palpitations, chest pain, nausea, vomiting, sweating, and a rapid increase in blood pressure, especially if they consume foods or beverages high in tyramine while taking isocarboxazid.
Dietary Restrictions: Due to the risk of hypertensive crisis, patients taking isocarboxazid must adhere to a strict dietary regimen that avoids foods and beverages containing high levels of tyramine, a compound found in aged, fermented, or spoiled foods. These include aged cheeses, cured meats, pickled or fermented foods, certain alcoholic beverages (especially beer and red wine), and some types of beans and nuts. Consuming these foods while taking isocarboxazid can lead to a sudden and dangerous increase in blood pressure.
Drug Interactions: Isocarboxazid can interact with a variety of medications and substances, including other antidepressants, certain pain medications (e.g., opioids), stimulants, decongestants, sympathomimetic agents, and certain herbal supplements. These interactions can potentiate the effects of isocarboxazid or other medications, leading to serious adverse reactions such as serotonin syndrome or hypertensive crisis.
Contraindications: Isocarboxazid is contraindicated in individuals with a history of hypersensitivity to the medication, severe liver disease, pheochromocytoma (a rare tumor of the adrenal glands), congestive heart failure, or a recent history of myocardial infarction. It should not be used concurrently with other MAOIs or within 14 days of discontinuing treatment with other MAOIs.
Monitoring: Patients taking isocarboxazid require regular monitoring of their blood pressure, especially during the initial weeks of treatment and following any dosage adjustments. Blood pressure should also be monitored if the patient experiences symptoms suggestive of hypertensive crisis.
Gradual Discontinuation: Discontinuing isocarboxazid should be done gradually under the supervision of a healthcare professional to minimize the risk of withdrawal symptoms or recurrence of depression.
Patient Education: Patients prescribed isocarboxazid should be educated about the importance of adhering to dietary restrictions, avoiding interactions with other medications or substances, monitoring for side effects, and seeking medical attention if they experience any concerning symptoms.
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Reduces |
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
ADHD | 1.6 | 1.6 | |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
Allergic Rhinitis (Hay Fever) | 1.6 | 0.5 | 2.2 |
Allergies | 1.7 | 0.6 | 1.83 |
Allergy to milk products | 0.5 | 1.3 | -1.6 |
Alzheimer's disease | 2.4 | 2.2 | 0.09 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.3 | 1.67 |
Ankylosing spondylitis | 1.4 | 0.6 | 1.33 |
Anorexia Nervosa | 0.7 | 1.3 | -0.86 |
Antiphospholipid syndrome (APS) | 0.7 | 0.3 | 1.33 |
Asthma | 2.3 | 1.1 | 1.09 |
Atherosclerosis | 1 | 0.6 | 0.67 |
Atrial fibrillation | 1.2 | 1.6 | -0.33 |
Autism | 2.6 | 3.1 | -0.19 |
Autoimmune Disease | 0.9 | 0.5 | 0.8 |
Barrett esophagus cancer | 0.3 | 0.3 | 0 |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 0.8 | 0.8 | |
Bipolar Disorder | 1.6 | 0.5 | 2.2 |
Brain Trauma | 0.3 | 0.8 | -1.67 |
Breast Cancer | 0.5 | 0.5 | |
Cancer (General) | 0.3 | 0.3 | |
Carcinoma | 2.5 | 0.7 | 2.57 |
Celiac Disease | 1.1 | 1 | 0.1 |
Cerebral Palsy | 0.6 | 0.8 | -0.33 |
Chronic Fatigue Syndrome | 1.2 | 1 | 0.2 |
Chronic Kidney Disease | 1.3 | 0.8 | 0.63 |
Chronic Lyme | 0.8 | -0.8 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.1 | 0.18 |
Chronic Urticaria (Hives) | 1.1 | 0.2 | 4.5 |
Coagulation / Micro clot triggering bacteria | 1.6 | 0.8 | 1 |
Cognitive Function | 1 | 0.8 | 0.25 |
Colorectal Cancer | 3.6 | 1.1 | 2.27 |
Constipation | 0.9 | 0.5 | 0.8 |
Coronary artery disease | 1.1 | 1 | 0.1 |
COVID-19 | 2.4 | 1.7 | 0.41 |
Crohn's Disease | 3.4 | 1.7 | 1 |
Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
cystic fibrosis | 0.9 | 0.8 | 0.13 |
d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
deep vein thrombosis | 1.3 | 1.1 | 0.18 |
Denture Wearers Oral Shifts | 1 | 1 | |
Depression | 3.2 | 2.4 | 0.33 |
Dermatomyositis | 0.3 | 0.3 | |
Eczema | 1.2 | 0.9 | 0.33 |
Endometriosis | 1.9 | 0.8 | 1.37 |
Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
Epilepsy | 1.9 | 0.9 | 1.11 |
erectile dysfunction | 1.2 | 1.2 | |
Fibromyalgia | 1.2 | 0.3 | 3 |
Functional constipation / chronic idiopathic constipation | 2.1 | 1.4 | 0.5 |
gallstone disease (gsd) | 1.4 | 0.8 | 0.75 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.3 | 1.33 |
Generalized anxiety disorder | 1.7 | 0.6 | 1.83 |
Glioblastoma | 0.3 | -0.3 | |
Gout | 0.6 | 0.6 | |
Graves' disease | 0.7 | 1.1 | -0.57 |
Gulf War Syndrome | 0.3 | 0.2 | 0.5 |
Halitosis | 1.1 | 0.3 | 2.67 |
Hashimoto's thyroiditis | 1.3 | 0.6 | 1.17 |
Heart Failure | 2.1 | 0.5 | 3.2 |
hemorrhagic stroke | 0.7 | 0.7 | |
Hidradenitis Suppurativa | 1.2 | 1.2 | |
High Histamine/low DAO | 0.8 | 0.8 | |
hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
hyperglycemia | 1.3 | 0.7 | 0.86 |
Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
hypersomnia | 0.3 | -0.3 | |
hypertension (High Blood Pressure | 1.8 | 1.6 | 0.13 |
Hypoxia | 1.6 | 1.6 | |
IgA nephropathy (IgAN) | 1.3 | 0.6 | 1.17 |
Inflammatory Bowel Disease | 3.1 | 2.1 | 0.48 |
Insomnia | 1.1 | 1.1 | 0 |
Intelligence | 0.6 | 0.6 | |
Intracranial aneurysms | 1 | 1 | |
Irritable Bowel Syndrome | 2.4 | 1.6 | 0.5 |
ischemic stroke | 1.3 | 1.4 | -0.08 |
Liver Cirrhosis | 3.6 | 2 | 0.8 |
Long COVID | 1.9 | 1.8 | 0.06 |
Low bone mineral density | 0.5 | -0.5 | |
Lung Cancer | 0.9 | 0.9 | |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 1.2 | 1.2 | |
ME/CFS with IBS | 0.3 | 0.3 | 0 |
ME/CFS without IBS | 0.3 | 0.3 | 0 |
membranous nephropathy | 0.3 | 0.3 | |
Menopause | 0.3 | 0.5 | -0.67 |
Metabolic Syndrome | 3.3 | 2.3 | 0.43 |
Mood Disorders | 2.9 | 2.3 | 0.26 |
multiple chemical sensitivity [MCS] | 0.8 | 0.8 | |
Multiple Sclerosis | 2.4 | 1.7 | 0.41 |
myasthenia gravis | 0.9 | 0.5 | 0.8 |
neuropathic pain | 1.3 | -1.3 | |
Neuropathy (all types) | 0.3 | 1.6 | -4.33 |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 0.8 | 1.87 |
NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
Obesity | 3 | 2.8 | 0.07 |
obsessive-compulsive disorder | 2 | 0.6 | 2.33 |
Osteoarthritis | 1.2 | 0.6 | 1 |
Osteoporosis | 1.4 | 0.6 | 1.33 |
pancreatic cancer | 0.6 | 0.3 | 1 |
Parkinson's Disease | 3.3 | 2.3 | 0.43 |
Polycystic ovary syndrome | 2.8 | 1.4 | 1 |
Premenstrual dysphoric disorder | 0.4 | -0.4 | |
primary biliary cholangitis | 0.3 | 0.6 | -1 |
Primary sclerosing cholangitis | 1.3 | 0.4 | 2.25 |
Psoriasis | 0.7 | 1.3 | -0.86 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.7 | 1.3 | 1.08 |
Rosacea | 0.5 | -0.5 | |
Schizophrenia | 1.6 | 1.3 | 0.23 |
scoliosis | 0.3 | 0.3 | 0 |
Sjögren syndrome | 1.3 | 0.7 | 0.86 |
Sleep Apnea | 0.3 | 0.8 | -1.67 |
Slow gastric motility / Gastroparesis | 0.5 | 0.5 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 1.1 | |
Stress / posttraumatic stress disorder | 1.8 | 1.3 | 0.38 |
Systemic Lupus Erythematosus | 2.3 | 0.6 | 2.83 |
Tic Disorder | 0.3 | 0.3 | |
Tourette syndrome | 0.3 | 0.3 | 0 |
Type 1 Diabetes | 1.6 | 1.1 | 0.45 |
Type 2 Diabetes | 3.1 | 2.3 | 0.35 |
Ulcerative colitis | 2.3 | 1.7 | 0.35 |
Unhealthy Ageing | 1.6 | 1 | 0.6 |
Vitiligo | 1.2 | 0.4 | 2 |